Management plans for populations with normal-to-hypertensive blood pressures: risks and benefits of antihypertensive drug treatment in populations previously defined as having high-normal blood pressure
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Recent changes in American and European guidelines on the management of arterial hypertension have caused a considerable shift in the landscape of hypertension management. The 2017 American College of Cardiology/American Heart Association/American Society of Hypertension guideline recommends an office visit blood pressure (BP) > 130/80 mmHg as the new threshold for diagnosis of hypertension, and states that the treatment goal for all hypertensive patients should be lowered to < 130/80 mmHg. In contrast, the 2018 European guideline maintains the diagnostic threshold of hypertension at 140/90 mmHg. However, despite their differences in thresholds for diagnosis of hypertension, both guidelines are in agreement that treatment should be considered in patients with BPs in the range of 130 to 139/80 to 89 mmHg if they have high cardiovascular risk. The results from the Systolic Blood Pressure Intervention Trial (SPRINT) study and recent meta-analyses suggest that BP lowering with antihypertensive treatment may be beneficial in reducing cardiovascular event rates in subjects with high-normal BP or stage 1 hypertension according to the new American guideline. However, intensive BP lowering is associated with increased incidence of treatment-associated adverse events, and evidence suggests that BP lowering below 120/70 mmHg increases the risk of cardiovascular events. In this review, we discuss the evidence supporting antihypertensive treatment in subjects with high-normal BP and discuss the specific subgroup of subjects that might benefit from BP lowering.
Abstract
Recent changes in American and European guidelines on the management of arterial hypertension have caused a considerable shift in the landscape of hypertension management. The 2017 American College of Cardiology/American Heart Association/American Society of Hypertension guideline recommends an office visit blood pressure (BP) > 130/80 mmHg as the new threshold for diagnosis of hypertension, and states that the treatment goal for all hypertensive patients should be lowered to < 130/80 mmHg. In contrast, the 2018 European guideline maintains the diagnostic threshold of hypertension at 140/90 mmHg. However, despite their differences in thresholds for diagnosis of hypertension, both guidelines are in agreement that treatment should be considered in patients with BPs in the range of 130 to 139/80 to 89 mmHg if they have high cardiovascular risk. The results from the Systolic Blood Pressure Intervention Trial (SPRINT) study and recent meta-analyses suggest that BP lowering with antihypertensive treatment may be beneficial in reducing cardiovascular event rates in subjects with high-normal BP or stage 1 hypertension according to the new American guideline. However, intensive BP lowering is associated with increased incidence of treatment-associated adverse events, and evidence suggests that BP lowering below 120/70 mmHg increases the risk of cardiovascular events. In this review, we discuss the evidence supporting antihypertensive treatment in subjects with high-normal BP and discuss the specific subgroup of subjects that might benefit from BP lowering.
참고문헌 (19)
- Whelton PK, "2017 ACC", AHA, ABC, pp.ACPM, AGS[DOI]
- Williams B, "2018 ESC", ESH guidelines for the management of arterial hypertension, 2018, pp.39, 3021~3104
- Lewington S, "Age-specific relevance of usual blood pressure to vascular mortality : a meta-analysis of individual data for one million adults in 61prospective studies", Lancet, 360, pp.1903~1913 (2002)
- Guo X, "Association between pre-hypertension and cardiovascular outcomes : a systematic review and meta-analysis of prospective studies", Curr Hypertens Rep, 15, pp.703~716 (2013)
- Lee M, "Presence of baseline prehypertension and risk of incident stroke : a meta-analysis", Neurology, 77, pp.1330~1337 (2011)
- Wang S, "Impact of baseline prehypertension on cardiovascular events and all-cause mortality in the general population : a meta-analysis of prospective cohort studies", Int J Cardiol, 168, pp.4857~4860 (2013)
- 윤남식, "Impact of High-Normal Blood Pressure Measured in Emergency Room on Adverse Cardiac Events in Acute Myocardial Infarction", Korean Circulation Journal, 42(5), pp.304~310 (2012), 대한심장학회
- 장신이, "Prehypertension and Left Ventricular Diastolic Dysfunction in Middle-Aged Koreans", Korean Circulation Journal, 46(4), pp.536~541 (2016), 대한심장학회
- Khera R, "Impact of 2017 ACC", AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China:nationally representative cross sectional study, 2018, pp.362, k2357~
- SPRINT Research Group, "A randomized trial of intensive versus standard blood-pressure control", N Engl J Med, 373, pp.2103~2116 (2015)
- Filipovsky J, "Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients", Blood Press, 25, pp.228~234 (2016)
- Ettehad D, "Blood pressure lowering for prevention of cardiovascular disease and death : a systematic review and meta-analysis", Lancet, 387, pp.957~967 (2016)
- Xie X, "Effects of intensive blood pressure lowering on cardiovascular and renal outcomes : updated systematic review and meta-analysis", Lancet, 387, pp.435~443 (2016)
- Brunstrom M, "Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels : a systematic review and meta-analysis", JAMA Intern Med, 178, pp.28~36 (2018)
- Lonn EM, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease", N Engl J Med, 374, pp.2009~2020 (2016)
- Thomopoulos C, "Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials", J Hypertens, 35, pp.2150~2160 (2017)
- Thomopoulos C, "Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs. discontinuations because of adverse drug events: meta-analyses of randomized trials", J Hypertens, 34, pp.1451~1463 (2016)
- Bohm M, "Achieved blood pressure and cardiovascular outcomes in high-risk patients : results from ONTARGET and TRANSCEND trials", Lancet, 389, pp.2226~2237 (2017)
- 김희진, "The J-curve between Diastolic Blood Pressure and Risk of All-cause and Cardiovascular Death", Korean Circulation Journal, 48(1), pp.36~47 (2018), 대한심장학회[DOI]